FEB 23, 2017 6:00 AM PST

Validation and Commercialization of Liquid Biopsy in a CLIA Lab

Speaker
  • President and CEO at Biocept
    Biography
      Mr. Nall has over 25 years of healthcare sales and marketing experience, most recently serving at Clarient Diagnostic Services, Inc. in positions of increasing responsibility from 2002 through August 2013, with his last position being General Manager, North American Sales and Marketing. While at Clarient, Mr. Nall was also responsible for leading the team assimilating Clarient into GE Healthcare after Clarient was acquired in 2010. From 1988 until joining Clarient, Mr. Nall served in the diagnostic and medical device industries in various commercial leadership roles for companies including Impath, American Cyanamid, Maquet Surgical, Strato Medical, Horizon Medical Products and Columbia Vital Systems. Mr. Nall received a Bachelor of Science degree in Business Administration from Central Missouri State University (now known as the University of Central Missouri).

    Abstract

    Liquid Biopsies are gaining acceptance in the Oncology community as a surrogate or complement to the gold standard of tissue biopsy.  A liquid biopsy provides biomarker information that a physician needs to understand in order to choose the best therapy for a patient. 

    Biocept is a San Diego, CA based company with cutting edge cancer diagnostics developed to capture and analyze circulating tumor cells (CTCs) as well as cell-free circulating tumor DNA (CtDNA).   The company has 18 patents issued on it’s proprietary technology that it uses to perform testing on patient samples through it’s CLIA and CAP accredited laboratory. 

    The company has validated 13 assays and currently markets these tests worldwide. 

    The talk will explain the company’s offerings in detail and also cover key points about the very large opportunity to help patients through liquid biopsy. 

    Learning Objective 1:Reasons why physicians use liquid biopsy today and where the uses are trending for the future

    Learning Objective 2:Biocept technology overview for both CTC and CTDNA capture and biomarker analysis

    Learning Objective 3:Validation results for Biocept Target Selector Assays

    Learning Objective 4: Partners for clinical validation along with publications, poster and abstract overview

     


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    DEC 02, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    OCT 08, 2020 7:00 AM PDT
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    Loading Comments...
    Show Resources
    Attendees
    • See more